BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24302567)

  • 1. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds.
    Pan MH; Lai CS; Tsai ML; Ho CT
    Mol Nutr Food Res; 2014 Jan; 58(1):147-71. PubMed ID: 24302567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
    Scorletti E; Byrne CD
    Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty liver: role of inflammation and fatty acid nutrition.
    Byrne CD
    Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data.
    Yki-Järvinen H
    Curr Opin Clin Nutr Metab Care; 2010 Nov; 13(6):709-14. PubMed ID: 20842026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant dietary approach in treatment of fatty liver: New insights and updates.
    Ferramosca A; Di Giacomo M; Zara V
    World J Gastroenterol; 2017 Jun; 23(23):4146-4157. PubMed ID: 28694655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling.
    Shabalala SC; Dludla PV; Mabasa L; Kappo AP; Basson AK; Pheiffer C; Johnson R
    Biomed Pharmacother; 2020 Nov; 131():110785. PubMed ID: 33152943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance.
    Asrih M; Jornayvaz FR
    J Endocrinol; 2013 Sep; 218(3):R25-36. PubMed ID: 23833274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease].
    Orlik B; Handzlik G; Olszanecka-Glinianowicz M
    Postepy Hig Med Dosw (Online); 2010 May; 64():212-9. PubMed ID: 20498498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance in nonalcoholic fatty liver disease.
    Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
    Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HlJ mice.
    Chen WY; Chen CJ; Liu CH; Mao FC
    Biochem Biophys Res Commun; 2010 Jul; 397(3):459-64. PubMed ID: 20513351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55.
    Collison KS; Saleh SM; Bakheet RH; Al-Rabiah RK; Inglis AL; Makhoul NJ; Maqbool ZM; Zaidi MZ; Al-Johi MA; Al-Mohanna FA
    Obesity (Silver Spring); 2009 Nov; 17(11):2003-13. PubMed ID: 19282820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism.
    Kim MH; Park JS; Jung JW; Byun KW; Kang KS; Lee YS
    Int J Obes (Lond); 2011 Aug; 35(8):1019-30. PubMed ID: 21157426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.
    Parekh S; Anania FA
    Gastroenterology; 2007 May; 132(6):2191-207. PubMed ID: 17498512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease.
    Papandreou D; Karabouta Z; Pantoleon A; Rousso I
    Appetite; 2012 Dec; 59(3):939-44. PubMed ID: 23000278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease.
    Martínez-Clemente M; Clària J; Titos E
    Curr Opin Clin Nutr Metab Care; 2011 Jul; 14(4):347-53. PubMed ID: 21587068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.